Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
Lists
Only you see this
Abstract
IHC testing should be performed to assess the HER2 status before the initiation of HER2-ADC therapy. There was a trend toward a better benefit for patients with <i>HER2</i> amplification, and tumor heterogeneity did not influence the drug efficacy.
BibTeX
@article{lei2023assessment,
author = {Huizi Lei and Yun Ling and Yuan Pei and Xieqiao Yan and Lin Wang and Yanxia Shi and Xin Yao and Hong Luo and Benkang Shi and Jiyan Liu and Zhisong He and Guohua Yu and Weiqing Han and Chang-Lu Hu and Zhihong Chi and Chuanliang Cui and Lu Si and Jianmin Fang and Jun Guo and Xinan Sheng and Aiping Zhou and Jianming Ying},
title = {{Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer}},
journal = {Journal of the National Cancer Center},
year = {2023},
doi = {10.1016/j.jncc.2023.02.003},
}Loading related content...